z-logo
open-access-imgOpen Access
Chronic toxicity study of Butea monosperma (Linn.) Kuntze seeds in albino rats
Author(s) -
Shilpa B Donga,
Vinay J Shukla,
B Ravishankar,
B K Ashok,
I U Mishtry
Publication year - 2011
Publication title -
ayu
Language(s) - English
Resource type - Journals
eISSN - 0976-9382
pISSN - 0974-8520
DOI - 10.4103/0974-8520.85743
Subject(s) - hematocrit , histopathology , toxicity , albumin , bone marrow , hemoglobin , bilirubin , triglyceride , globulin , medicine , endocrinology , biology , andrology , pathology , cholesterol
In the present study, toxic effects of powder of seeds of Butea monosperma (Linn.) Kuntze were evaluated for a period of 3 months in albino rats. Control group received distilled water. The powder suspension was orally given to the treated group at a dose of 800 mg/kg/day for 90 days. Parameters like body weight, weight of important organs, biochemical, hematological parameters, bone marrow cytology and histopathology of vital organs were studied. Test drug administration did not affect the body weight, organ weight and bone marrow cytology to a significant extent. Among the 18 hematological parameters studied, significant changes were observed in three parameters, namely, significant decrease in hemoglobin content, red blood cell count and hematocrit. Of 16 biochemical parameters studied, significant changes were observed in 5 parameters, namely, decrease in total protein, albumin, bilirubin and significant increase in very low density lipoprotein and triglyceride. The histopathology of 18 organs revealed changes such as fatty changes, glomerular congestion and tubular hemorrhage in the kidneys, decrease in the cellularity of the spleen, epithelial disruption in jejunum, decrease in spermatogenesis in the testis, epithelial proliferation in ventral prostate and decrease in epithelial proliferation in the uterus. Thus, toxicity profile obtained from the present study shows that B. monosperma seeds are likely to produce toxic effect when administered in a powder form.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here